ExScientia Ltd

Exscientia Plc operates as an AI-driven pharmatech company which is engaged in designing and developing patient-based drugs. The firm has designed three drugs that are in phase 1 human clinical trials. The company was founded by Andrew L. Hopkins in 2012 and is headquartered in Oxford, the United Kingdom.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

ExScientia reports robust Q4 earnings, poised for precision medicine growth

ExScientia's Q4 2022 earnings call highlighted strong financial performance, key collaborations, and advancements in pipeline programs. The company's focus on AI-driven precision medicine and solid cash position bode well for future growth. Challenges in program management and cost control exist, but opportunities for innovation and partnerships are abundant.

ExScientia reports 15% revenue growth, poised for precision medicine leadership

ExScientia Ltd delivered strong financial performance with a 15% increase in quarterly revenue and a robust cash position, driven by successful product launches and cost-saving initiatives.
The company's focus on personalized medicine, innovative product development, and strategic financial management positions it well for future growth and market leadership.
While facing challenges in molecule differentiation and cost efficiency, ExScientia has opportunities to leverage biomarkers, advance clinical programs, and expand market presence.

ExScientia advances clinical trials and precision medicine with strong financials

ExScientia's Q2 2023 earnings call showcased progress in clinical trials, precision medicine, and AI integration, supported by a strong financial position.
The company's focus on innovation, cost efficiency, and strategic partnerships positions them well for future growth and advancements in drug discovery.
Challenges lie in managing milestone payments, operational complexities, and staying competitive through biologics investments and partnerships.
Opportunities abound in expanding collaborations, attracting industry interest, and unveiling advancements in biologics for pipeline growth from 2024 onwards.

ExScientia excels in Q3, poised for growth in precision medicine

ExScientia's Q3 performance reflects progress in oncology programs, financial strength, and a focus on precision drug design and partnerships.
The company's strengths lie in its robust cash position, innovative approach to drug design, and operational efficiency influenced by past projects.
Challenges include market adaptability, program prioritization, and maintaining competitiveness, while opportunities exist in advancing the pipeline and leveraging partnerships for growth.

ExScientia reports robust Q4 earnings, eyes growth through innovation

ExScientia's Q4 2023 earnings call showcases strong financial and operational performance.
The company's focus on innovation, partnerships, and efficiency drives growth.
Challenges include competition, innovation sustainability, and quality maintenance.
Opportunities lie in business development, automation, and efficient drug creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Exscientia Plc engages in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of therapeutic compounds. The company was founded by Andrew L. Hopkins in 2012 and is headquartered in Oxford, the United Kingdom.

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Exscientia p.l.c. (“Exscientia” or the “Company”) (NASDAQ: EXAI) securities between March 23, 2022 and Febraury 12, 2024, inclusive (the “Class Period”). Exscientia investors have until June 25, 2024 to file a lead plaintiff motion. Investors suffering losses on their Exscientia investments are encouraged to contact the Law Offices of Howard G.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Exscientia p.l.c.

NEW YORK , May 3, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Exscientia plc (NASDAQ: EXAI). Shareholders who purchased shares of EXAI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Investors in Exscientia plc Should Contact The Gross Law Firm Before June 25, 2024 to Discuss Your Rights - EXAI

NEW YORK , May 3, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Exscientia plc ("Exscientia" or the "Company") (NASDAQ: EXAI) and reminds investors of the June 25, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Exscientia To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 investing in Exscientia stock or options between March 23, 2022, and February 12, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext.

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Exscientia

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Exscientia p.l.c. (“Exscientia” or the “Company”) (NASDAQ: EXAI) investors concerning the Company's possible violations of federal securities laws. On February 13, 2024, Exscientia announced that its CEO and Principal Executive Officer, Andrew Hopkins, had been terminated following an investigation which found that he had “engaged in relationships with two employees that the Board determined w.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Exscientia p.l.c.

SAN DIEGO--(BUSINESS WIRE)---- $EXAI #EXAI--Robbins LLP is Investigating the Allegations that Exscientia plc's (EXAI) Former CEO's Conduct Violated the Company's Code of Business Conduct.

Exscientia plc (EXAI) Investor Notice: Robbins LLP Reminds Stockholders of the Exscientia plc Class Action

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Exscientia p.l.c. (“Exscientia” or the “Company”) (NASDAQ: EXAI) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Exscientia investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securiti.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Exscientia p.l.c. (EXAI) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Exscientia p.l.c. (“Exscientia” or the “Company”) (NASDAQ: EXAI) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On February 13, 2024, Exscientia announced that its CEO and Principal Executive Officer, Andrew Hopkins, had been terminated following an investigation which found that he.

The Law Offices of Frank R. Cruz Announces Investigation of Exscientia p.l.c.

NEW YORK , May 1, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Exscientia plc (NASDAQ: EXAI) between March 23, 2022 and February 12, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.

ROSEN, LEADING INVESTOR COUNSEL, Encourages Exscientia plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - EXAI

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Exscientia plc (NASDAQ: EXAI) between March 23, 2022 and February 12, 2024, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 25, 2024. SO WHAT: If you purchased Exscientia securities during the Class Peri.

ROSEN, A TOP RANKED LAW FIRM, Encourages Exscientia plc Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – EXAI

Guardforce AI Co Ltd

Microbot Medical

Excitement over the prospects for artificial intelligence (AI) continues to be a significant driver for many stocks, including several of the so-called Magnificent Seven.

3 AI Stocks Wall Street Expects to Return Up to 595% in 2024

NEW YORK, NY / ACCESSWIRE / March 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Exscientia plc ("Exscientia plc") (NASDAQ:EXAI) concerning possible violations of federal securities laws. Exscientia issued a press release, on February 13, 2024, "announc[ing] that its Board of Directors (the ‘Board') has decided to terminate the employment of Andrew Hopkins as the Company's Chief Executive Officer and Principal Executive Officer, and to remove Dr. Hopkins from his role as an Executive Director of the Board, in each case for cause and effective immediately.

Investors who lost money on Exscientia plc should contact Levi & Korsinsky about an ongoing investigation - EXAI

NEW YORK, NY / ACCESSWIRE / March 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Exscientia plc ("Exscientia plc") (NASDAQ:EXAI) concerning possible violations of federal securities laws. Exscientia issued a press release, on February 13, 2024, "announc[ing] that its Board of Directors (the ‘Board') has decided to terminate the employment of Andrew Hopkins as the Company's Chief Executive Officer and Principal Executive Officer, and to remove Dr. Hopkins from his role as an Executive Director of the Board, in each case for cause and effective immediately.

Levi & Korsinsky Reminds Exscientia plc Investors of the Ongoing Investigation into Potential Violations of Securities Laws - EXAI

NEW YORK, NY / ACCESSWIRE / March 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Exscientia plc ("Exscientia plc") (NASDAQ:EXAI) concerning possible violations of federal securities laws. Exscientia issued a press release, on February 13, 2024, "announc[ing] that its Board of Directors (the ‘Board') has decided to terminate the employment of Andrew Hopkins as the Company's Chief Executive Officer and Principal Executive Officer, and to remove Dr. Hopkins from his role as an Executive Director of the Board, in each case for cause and effective immediately.

EXAI ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Exscientia plc

Exscientia plc (EXAI) Q4 2023 Earnings Call Transcript

NEW YORK, NY / ACCESSWIRE / March 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Exscientia plc ("Exscientia plc") (NASDAQ:EXAI) concerning possible violations of federal securities laws. Exscientia issued a press release, on February 13, 2024, "announc[ing] that its Board of Directors (the ‘Board') has decided to terminate the employment of Andrew Hopkins as the Company's Chief Executive Officer and Principal Executive Officer, and to remove Dr. Hopkins from his role as an Executive Director of the Board, in each case for cause and effective immediately.

Lost Money on Exscientia plc(EXAI)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

OXFORD, U.K.--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) Recent advancements in the Company's pipeline, collaborations and operations, as well as financial results for the fourth quarter and full year 2023, are summarised below. Exscientia will host a conference call Thursday, March 21 at 12:30 p.m. GMT / 8:30 a.m. EDT. “In 2023, we significantly expanded our technological capabilities with the opening of our automation facility, concentrated our internal research on high value oncology tar.

Exscientia Business and Financial Update for the Full Year 2023

NEW YORK, NY / ACCESSWIRE / March 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Exscientia plc ("Exscientia plc") (NASDAQ:EXAI) concerning possible violations of federal securities laws. Exscientia issued a press release, on February 13, 2024, "announc[ing] that its Board of Directors (the ‘Board') has decided to terminate the employment of Andrew Hopkins as the Company's Chief Executive Officer and Principal Executive Officer, and to remove Dr. Hopkins from his role as an Executive Director of the Board, in each case for cause and effective immediately.

An Investigation Has Commenced on Behalf of Exscientia plc Shareholders. Contact Levi & Korsinsky to Discuss your EXAI Losses.

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) will report financial results for the fourth quarter and full year ended December 31, 2023, on Thursday, March 21, 2024, before the open of U.S. markets. The Company will host a conference call and webcast at 12:30 p.m. GMT / 8:30 a.m. EDT to provide a business update and review financial results. A webcast of the live call can be accessed by visiting the “Investors and Media” section of the Company's website at investors.exscienti.

Exscientia to Report Full Year 2023 Financial Results on March 21, 2024

NEW YORK, NY / ACCESSWIRE / March 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Exscientia plc ("Exscientia plc") (NASDAQ:EXAI) concerning possible violations of federal securities laws. Exscientia issued a press release, on February 13, 2024, "announc[ing] that its Board of Directors (the ‘Board') has decided to terminate the employment of Andrew Hopkins as the Company's Chief Executive Officer and Principal Executive Officer, and to remove Dr. Hopkins from his role as an Executive Director of the Board, in each case for cause and effective immediately.

Levi & Korsinsky Investigates Possible Securities Fraud Violations by Exscientia plc (EXAI)

NEW YORK,, March 11, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Exscientia plc ("Exscientia" or the "Company") (NASDAQ: EXAI).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Exscientia plc - EXAI

NEW YORK, NY / ACCESSWIRE / March 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Exscientia plc ("Exscientia plc") (NASDAQ:EXAI) concerning possible violations of federal securities laws. Exscientia issued a press release, on February 13, 2024, "announc[ing] that its Board of Directors (the ‘Board') has decided to terminate the employment of Andrew Hopkins as the Company's Chief Executive Officer and Principal Executive Officer, and to remove Dr. Hopkins from his role as an Executive Director of the Board, in each case for cause and effective immediately.

Levi & Korsinsky, LLP Investigates Possible Securities Fraud Violations by Exscientia plc (EXAI)

NEW YORK, NY / ACCESSWIRE / March 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Exscientia plc ("Exscientia plc") (NASDAQ:EXAI) concerning possible violations of federal securities laws. Exscientia issued a press release, on February 13, 2024, "announc[ing] that its Board of Directors (the ‘Board') has decided to terminate the employment of Andrew Hopkins as the Company's Chief Executive Officer and Principal Executive Officer, and to remove Dr. Hopkins from his role as an Executive Director of the Board, in each case for cause and effective immediately.

EXAI STOCK ALERT: Levi & Korsinsky Notifies Exscientia plc Investors of an Ongoing Investigation

Levi & Korsinsky Reminds Shareholders of an Investigation into Exscientia plc (EXAI) Regarding Potential Securities Fraud Allegations

NEW YORK, NY / ACCESSWIRE / March 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Exscientia plc ("Exscientia plc") (NASDAQ:EXAI) concerning possible violations of federal securities laws. Exscientia issued a press release, on February 13, 2024, "announc[ing] that its Board of Directors (the ‘Board') has decided to terminate the employment of Andrew Hopkins as the Company's Chief Executive Officer and Principal Executive Officer, and to remove Dr. Hopkins from his role as an Executive Director of the Board, in each case for cause and effective immediately.

EXAI ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Exscientia plc

NEW YORK, NY / ACCESSWIRE / March 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Exscientia plc ("Exscientia plc") (NASDAQ:EXAI) concerning possible violations of federal securities laws. Exscientia issued a press release, on February 13, 2024, "announc[ing] that its Board of Directors (the ‘Board') has decided to terminate the employment of Andrew Hopkins as the Company's Chief Executive Officer and Principal Executive Officer, and to remove Dr. Hopkins from his role as an Executive Director of the Board, in each case for cause and effective immediately.

News for ExScientia Ltd Stock (EXAI)